MS Immune System Study

A study of immune phenotype biomarkers in patients with Relapsing Multiple Sclerosis (RMS) after treatment with 0.5mg fingolimod (Gilenya).

Participation lasts about a year and requires 4 blood samples to be taken: at your first study visit, after you qualify, and at approximately 3,6, and 12 months.

You may qualify for compensation for time and travel.

 

Contact Us!